Searched for
INSULIN GLARGINE
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billionBiocon's Executive Chairperson, Kiran Mazumdar-Shaw, outlined a five-year leadership transition with her niece, Claire Mazumdar, as success...- Biocon Biologics expands collaboration with Civica to supply affordable insulin in USBiocon Biologics is expanding its partnership with Civica. This new agreement will bring affordable Insulin Glargine to patients in the Uni...
- Eris Lifesciences enters licensing deal with Biocon for insulin glargineThe launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its reve...
- Biocon Biologics set to reap biosimilar insulin glargine opportunity in USDrugmaker Biocon is banking on the ramp-up of interchangeable biosimilar insulin glargine expecting the product to boost the revenue and pr...
- Biocon's interchangeable biosimilar Insulin glargine added on Express Scripts’ largest formulary in USThe listing is expected to boost Biocon's biosimilar business, as inclusion of Semglee on Express Scripts' NPF will allow pharmacies to sub...
- Biocon Biologics launches Semglee, drug to control high blood sugar, in USTo encourage broad patient access to this important medicine, Mylan is offering Semglee at a wholesale acquisition cost (WAC)[1] of $147.98...
- Biocon says probe on Malaysia manufacturing unit ends“This is to inform you that Biocon Sdn Bhd, a subsidiary of Biocon, has received the EIR from the USFDA for the pre-approval inspection of ...
- Biocon, Mylan win US court ruling in favour of insulin GlargineUS District Court of New Jersey found the device patent claims (US Patent No. 9526844) asserted by Sanofi against Biocon and Mylan’s insuli...
- Biocon gets 3 USFDA observations for insulin facility in MalaysiaUSFDA had conducted a pre-approval inspection of Biocon's subsidiary Biocon Sdn BHd's manufacturing facility in Malaysia for Insulin Glargi...
- Biocon, Mylan launch insulin biosimilar in AustraliaThe biotechnology major and pharmaceutical company Mylan N V announced the launch of their insulin biosimilar Semglee.
- USFDA issues response letter for new drug application for insulin glargine: BioconBiocon is confident of addressing these observations through a corrective and preventive action plan in a timely manner, it added.
- Biocon's Malaysian arm gets EU GMP certification for insulin manufacturing facilityThe integrated insulins facility in Malaysia manufactures drug substance and drug products in vials, cartridges, and insulin delivery devic...
- Mylan-Biocon’s insulin biosimilar faces FDA hurdleFirms have been asked to share details about a change in the manufacturing site for glargine from Bengaluru to a new facility in Malaysia.
- European Medicines Agency accepts marketing application of Biocon, Mylan productMylan and Biocon, which have co-developed insulin glargine, look forward to offering another insulin treatment option for diabetic patients.
- Biocon's partner firm launches diabetes product in JapanIn March this year, Biocon received approval from the Japanese health authority to sell its biosimilar product Insulin Glargine.
- Biocon gets nod to sell its diabetes product 'Insulin Glargine' in JapanBiocon has received approval from the Japanese health authority to sell its biosimilar product 'Insulin Glargine' in that country.
- Biocon rallies intraday after getting approval for insulin Glargine in Mexico, but ends in redBiocon rallied a little over 3% in trade on Friday, after the biotechnology major said that it has received approval for its insulin Glargi...
- Biocon gets approval for insulin Glargine in MexicoGalactus by PiSA is the first insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012, it adde...
- Lupin inks pact with South Korean firm to launch diabetes drugAs per the strategic distribution pact inked between the two companies, Mumbai-based Lupin will launch LG Life Sciences' Insulin Glargine.
- Wockhardt, Biocon under NPPA scannerWockhardt and Biocon have come under the drug price regulator National Pharmaceutical Pricing Authority (NPPA) scanner for allegedly violat...
Load More
